Vamsidhar Velcheti

Oncology

160 E 34th St
New York, NY 10016

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 171 publications

Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.

Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 14, 2026

Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.

Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.

Journal: Future oncology (London, England)

Published: July 30, 2026

Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non-Small Cell Lung Cancer.

Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non-Small Cell Lung Cancer.

Journal: JCO oncology practice

Published: June 29, 2026

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 14, 2026

Emerging Immunotherapy and Antibody-Derived Therapeutics for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Review.

Emerging Immunotherapy and Antibody-Derived Therapeutics for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Review.

Journal: Cancers

Published: March 13, 2026

QVT score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy.

QVT score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: January 30, 2026

Immune Checkpoint Inhibitors in Unresectable or Metastatic Thymic Epithelial Tumors--A Real-World Assessment of Efficacy and Toxicity.

Immune Checkpoint Inhibitors in Unresectable or Metastatic Thymic Epithelial Tumors--A Real-World Assessment of Efficacy and Toxicity.

Journal: Clinical lung cancer

Published: December 22, 2025

5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.

5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.

Journal: Immunotherapy

Published: October 17, 2025

Treatment-free survival with first-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: a critical analysis beyond PD-L1 expression.

Treatment-free survival with first-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: a critical analysis beyond PD-L1 expression.

Journal: Journal of thoracic disease

Published: September 12, 2025

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

Journal: The oncologist

Published: August 27, 2025

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

Journal: The oncologist

Published: August 27, 2025

Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.

Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 18, 2025

Showing 1-12 of 171

Last Updated: 09/26/2026